Cerebral
Cerebral is an online mental health platform offering therapy, psychiatry, and medication management through a subscription-based telehealth model. The service connects patients with licensed therapists and prescribers for conditions including anxiety, depression, insomnia, and ADHD.
Score generated by AI agents based on publicly cited evidence and reviewed by the project maintainer. Not independently validated.
Score History
Timeline events are AI-curated from public reporting. Score trajectory is derived from documented events.
Cerebral launched in January 2020 just as COVID-19 created unprecedented demand for remote mental healthcare. The company offered a straightforward subscription model for therapy and medication management with minimal dark patterns or extraction mechanisms. Early tracking pixel deployment on the website began sharing data with advertisers from October 2019 (predating the company's own founding date as registered). VC-funded growth incentives were present but not yet driving clinical decisions.
Cerebral raised $462 million across three rounds in under two years, reaching a $4.8 billion SoftBank-led valuation. The growth-at-all-costs strategy was now visibly corrupting clinical operations: the company implemented undisclosed prescribing metrics targeting 95-100% stimulant prescription rates for ADHD patients, with financial incentives and threatened disciplinary measures for non-compliant providers. Tracking pixels continued sharing patient health data with Facebook, Google, TikTok and others. Negative-option billing with deliberately burdensome cancellation processes was fully operational. The Simone Biles partnership and $5M+ in Instagram advertising fueled aggressive patient acquisition.
The convergence of the Wall Street Journal prescribing exposé, Matthew Truebe's whistleblower lawsuit, the DOJ grand jury subpoena, and the CBS News investigation transformed Cerebral from a pandemic success story into a case study in telehealth abuse. CEO Kyle Robertson was terminated, controlled substance prescribing was halted entirely, and the company began bleeding patients and employees. The Simone Biles partnership collapsed. Mass layoffs eliminated over 1,000 workers including 400 of 500 care counselors, while pharmacy partner Truepill faced DEA action for filling 72,000 problematic prescriptions.
Cerebral disclosed the tracking pixel breach affecting 3.18 million patients to HHS, triggering class action litigation and marking the second-largest patient data breach of 2023. The company closed its opioid MAT program and executed a third round of layoffs (15% of remaining staff). The NY Attorney General investigation revealed Cerebral had instructed employees to post fake positive reviews and suppress negative ones. The Robertson $50M loan lawsuit exposed governance failures. Total workforce was now roughly 35% smaller than its 2022 peak. Regulatory penalties had not yet landed, but investigations by the FTC, DOJ, and state AGs were all active.
Regulatory enforcement actions crystallized: the FTC imposed a $7 million settlement (reduced from $15M due to inability to pay) and a first-of-its-kind permanent ban on health data advertising. The DOJ/DEA levied a $3.6 million fine for the prescribing scheme with an additional $2.9 million deferred. Founder Robertson's new company Zealthy was added to the federal complaint. The company's financial fragility was laid bare when it revealed it could not pay the full civil penalty. However, the settlements themselves represented accountability and the beginning of mandated reform rather than further deterioration.
Cerebral is in a nascent recovery phase following the resolution of its major regulatory enforcement actions. The FTC distributed $5.1 million in refunds and permanently banned health data sharing for advertising. The company acquired Resilience Lab in August 2025 to improve clinical quality and reduce provider turnover, raised $25 million in new capital, and established the Cerebral Institute for clinician training. However, deep structural damage from the growth-at-all-costs era persists: the company still cannot prescribe controlled substances, governance instability continues with a third CEO (interim), and the financial fragility exposed by its inability to pay full penalties remains a concern.
Alternatives
Therapist directory offering reduced-cost sessions ($30-80/session) from licensed providers — a non-corporate alternative for people who don't need psychiatric medication management. No subscription model, no upsells. Moderate switch — you're finding a therapist directly rather than using a managed platform, which requires more upfront research but avoids platform data practices entirely.
Online therapy platform with psychiatry and medication management — a direct alternative to Cerebral's core services but without the DEA investigation, FTC data privacy violations, and documented high-pressure prescribing practices. Scores 51 vs. Cerebral's 56. Moderate switch — you'll need to transfer or restart your care relationship, but the underlying clinical model is safer.
Dimensional Breakdown
Summaries below were written by AI agents based on the cited evidence. They are editorial interpretations, not independent research findings.
Dimension History
Timeline (37 events)
Cerebral founded by Kyle Robertson and Ho Anh
Kyle Robertson and Dr. Ho Anh, a former medical director at telehealth company Hims, co-founded Cerebral as an online mental health subscription service. The company launched at the onset of the COVID-19 pandemic, positioning itself to capitalize on surging demand for remote mental healthcare.
Cerebral raises $35M Series A led by Oak HC/FT
Cerebral raised $35 million in Series A funding led by Oak HC/FT, with participation from WestCap, Liquid 2 Ventures, and Gaingels. The funds were directed toward expanding to all 50 states, building a mobile app, and securing in-network insurance partnerships. The company had grown from 5 to over 1,000 employees since its January launch.
Cerebral implements prescribing metrics to boost stimulant prescriptions
From May 2021, Cerebral implemented internal metrics tracking the Initial Visit Rx Rate with a target of 95% and began tracking stimulant prescribing rates for ADHD patients. The company paid providers an additional $10 per prescription-related PDMP database check as a financial incentive. These metrics were not clinically justified and prioritized revenue retention over patient safety.
Cerebral failed to block former employees from accessing patient records
From May to December 2021, Cerebral failed to revoke former employees' access to confidential electronic medical records, allowing unauthorized access to sensitive patient data including diagnoses, medications, and contact information. The FTC later cited this as evidence of the company's failure to implement adequate security guardrails.
Cerebral raises $127M Series B, reaches $1.2B unicorn valuation
Cerebral raised $127 million in Series B funding led by Access Industries (Len Blavatnik), with participation from Silver Lake Waterman, Artis Ventures, and Bill Ackman. The round pushed Cerebral's valuation to $1.23 billion, making it a unicorn less than 18 months after founding. Funds were earmarked for expanding into group therapy, couples counseling, and new treatment areas.
Simone Biles joins Cerebral as Chief Impact Officer
Olympic gold medalist Simone Biles partnered with Cerebral as Chief Impact Officer, three months after withdrawing from individual competition at the Tokyo Olympics to protect her mental health. The strategic partnership included financial commitments to providing mental health services in underserved communities and Cerebral's sponsorship of the Gold Over America Tour.
Cerebral sets ADHD stimulant prescribing target to 100%
From October 2021, Cerebral instituted an internal plan to increase the ADHD Stimulant Rx Metric to 100% for patients without comorbidities. The plan included auditing individual providers' ADHD prescription practices and considering disciplinary measures for providers who did not prescribe enough stimulants. The company's chief medical officer allegedly told employees the goal was to prescribe stimulants to all ADHD patients.
SoftBank leads $300M Series C at $4.8B valuation
Cerebral closed a $300 million Series C round led by SoftBank Vision Fund 2, with Prysm Capital, Access Industries, and WestCap Group participating. The valuation quadrupled to $4.8 billion, bringing total funding to $462 million. The company announced plans for international expansion and M&A to become a 'one-stop shop for behavioral care.'
Instagram and TikTok pull Cerebral ADHD ads for misleading health claims
Meta and TikTok removed Cerebral advertisements after NBC News inquiries revealed the ads linked ADHD to obesity with images of junk food, stating obesity is 'five times more prevalent' among adults with ADHD. The ads were found to violate platform policies against promoting misleading health claims and generating negative self-perception to sell health products.
Cerebral announces plans to hire 500 additional employees
At its peak, Cerebral announced plans to hire 500 new full-time employees to support its more than 420,000 customers. The workforce had grown from 5 employees at founding to over 1,000. Within months, the company would reverse course and begin a series of mass layoffs that would reduce headcount by roughly 35%.
Wall Street Journal reports nurse practitioners felt pressured to prescribe stimulants
The Wall Street Journal reported that Cerebral nurse practitioners felt pressured to prescribe Adderall and other ADHD stimulants, citing the company's 30-minute telehealth sessions as insufficient to properly diagnose ADHD. Providers described being told to prescribe first and evaluate later, raising patient safety concerns.
Former VP Matthew Truebe files whistleblower lawsuit alleging overprescribing
Matthew Truebe, former VP of product and engineering, filed a labor lawsuit claiming Cerebral fired him after he raised concerns about overprescription. He alleged the company aimed to prescribe stimulants to 100% of ADHD patients for retention purposes, found over 2,000 duplicate shipping addresses suggesting prescription fraud, and was retaliated against with a negative performance evaluation and stock option cuts.
DOJ serves grand jury subpoena for controlled substances investigation
The U.S. Attorney's Office for the Eastern District of New York served Cerebral with a grand jury subpoena relating to possible violations of the Controlled Substances Act. The subpoena requested documents dating back to Cerebral's 2020 launch, including controlled substance policies, financial records, and procedures to detect prescription fraud.
Cerebral pauses new controlled substance prescriptions for ADHD
On the same day it received the DOJ subpoena, Cerebral announced it would stop writing new prescriptions for controlled substances treating ADHD, including Adderall, Ritalin, and Vyvanse. The pause applied to new patients effective May 9, with existing patients transitioned off controlled substances by October 15.
CEO Kyle Robertson terminated, David Mou named replacement
Cerebral's board of directors terminated founder and CEO Kyle Robertson amid the DOJ investigation and prescribing controversy. Chief Medical Officer David Mou was promoted to CEO. Robertson was immediately at odds with the company, later claiming investors pushed him to prescribe controlled drugs and used him as a scapegoat.
Cerebral stops prescribing all controlled substances
Cerebral announced it would stop prescribing most controlled substances entirely, including stimulants like Adderall and Xanax, for both new and existing patients. New patients were cut off immediately; existing patients were transitioned by October 15. The company continued prescribing only medications for opioid use disorder. This eliminated a core value proposition for ADHD patients.
First round of layoffs announced amid DOJ investigation
Cerebral announced its first round of layoffs effective July 1, citing a focus on quality and operational efficiency. The company did not disclose specific numbers. This came just weeks after the CEO ouster and DOJ subpoena, marking the beginning of a contraction that would see the workforce reduced by roughly 35% over three rounds.
CBS News investigation reveals staff practiced with expired licenses
CBS News reported that documents showed Cerebral leadership was informed about staff practicing with expired or suspended licenses, patient safety issues, and hires who did not meet company standards. An internal log showed nearly 1,200 instances of prescribers being unresponsive to patients over 11 months. Some patients received prescriptions and were then unable to reach their prescriber for safety instructions.
Media Matters finds Cerebral spent $5M+ on Instagram ADHD ads
Media Matters reported that Cerebral spent more than $5 million on Instagram advertising since January 2022, generating over 630 million impressions. Despite having paused prescribing controlled substances, the company continued running ads for ADHD diagnoses and other services on the platform, raising questions about patient acquisition motives.
Cerebral lays off 20% of workforce, over 1,000 employees
Cerebral announced its second and largest round of layoffs, cutting 20% of its workforce or more than 1,000 employees from a headcount of approximately 5,500. Roughly 400 of 500 care counselors were eliminated. CEO David Mou stated the cuts were made to 'best serve our clients,' but the scale reflected post-pandemic demand contraction and the loss of the controlled substance prescribing business.
Cerebral sues ousted CEO Kyle Robertson over unpaid $50M loan
Cerebral filed a lawsuit in New York Supreme Court alleging founder Kyle Robertson defaulted on a nearly $50 million loan taken in January 2022 to purchase 1.06 million shares of company stock. Robertson owed 51% of the principal ($25.4 million) plus interest, which was due within six months of his May termination. Robertson allegedly refused to repay despite his contractual obligation.
Simone Biles ends partnership with Cerebral
Olympic gold medalist Simone Biles declined to renew her endorsement contract with Cerebral, ending her role as Chief Impact Officer. The split came seven months after the DOJ investigation surfaced and amid ongoing prescribing controversies. Reports indicated CEO Robertson had pressed Biles to promote Cerebral's prescription services specifically.
DEA serves order to show cause against pharmacy partner Truepill
The DEA issued an Order to Show Cause against Truepill, Cerebral's pharmacy fulfillment partner, for unlawfully dispensing controlled substance prescriptions. Between September 2020 and September 2022, Truepill filled over 72,000 controlled substance prescriptions, 60% of which were stimulants. The DEA found prescriptions that exceeded supply limits and were written by prescribers lacking proper state licensing.
Cerebral closes MAT program and lays off 15% of remaining staff
Cerebral quietly closed its medication-assisted treatment program for opioid use disorder, transitioning fewer than 20 remaining OUD patients to alternative care. Simultaneously, the company laid off approximately 250 employees, about 15% of its remaining workforce. This was the third round of layoffs in less than a year, bringing total workforce reductions to roughly 35%.
Cerebral discloses 3.1M patient data breach from tracking pixels
Cerebral filed a breach notification with HHS and sent letters to users acknowledging that tracking pixels on its website and apps had shared personal health information of 3,179,835 patients with Facebook, Google, TikTok, and other third parties since October 2019. Exposed data included names, birthdates, IP addresses, mental health self-assessments, insurance details, and treatment information.
Class action lawsuit filed over tracking pixel data breach
A class action lawsuit was filed in California federal court alleging Cerebral violated state and federal privacy laws by sharing patient data with tech platforms through embedded tracking pixels. The lawsuit sought damages for the estimated 3.2 million patients whose mental health information was disclosed to advertisers without consent.
NY Attorney General secures $740,000 for deceptive cancellation practices
New York Attorney General Letitia James secured more than $740,000 from Cerebral, including $540,162 in restitution to 16,552 consumers and $200,000 in penalties. The investigation found Cerebral required email-based cancellations with additional steps and up to a week's delay, charged consumers when delays crossed billing dates, and instructed employees to post fake positive reviews and suppress negative ones.
FTC imposes $7M settlement and permanent health data advertising ban
The FTC and DOJ filed a settlement requiring Cerebral to pay a $7 million fine (reduced from $15 million due to inability to pay) for sharing 3.2 million patients' health data with advertisers and deceptive cancellation practices. The order included a first-of-its-kind permanent ban on using health information for advertising, mandatory consumer notifications, and optional data deletion. The FTC also alleged Cerebral sent promotional postcards without envelopes to 6,000+ patients, revealing diagnoses.
Cerebral reveals inability to pay full $10M FTC civil penalty
Court filings revealed Cerebral could not afford to pay the full $10 million civil penalty, which was suspended after a $2 million payment. Combined with the $5.1 million in consumer refunds and other settlement costs, the financial fragility exposed how the VC-funded growth-at-all-costs model left the company hollowed out despite raising $462 million in total funding.
DOJ adds founder's new company Zealthy to FTC complaint
The DOJ and FTC filed an amended complaint adding Zealthy Inc. (later renamed Gronk Inc.), founded by ex-Cerebral CEO Kyle Robertson, to the existing case. The complaint alleged Robertson continued identical deceptive practices at Zealthy: sharing patient data with advertisers without consent, misrepresenting cancellation policies, and failing to obtain informed consent for subscription charges.
DOJ/DEA levies $3.6M fine for pushing controlled substance prescriptions
Cerebral entered a non-prosecution agreement with the U.S. Attorney's Office for the Eastern District of New York, paying $3,652,000 in forfeiture for exploiting telehealth flexibilities to boost stimulant prescriptions. An additional $2,922,000 penalty was deferred due to inability to pay. The DOJ documented that Cerebral used financial incentives and considered disciplinary measures to pressure providers into meeting prescribing metrics from 2021 to 2022.
CEO David Mou steps down, third CEO transition in three years
David Mou departed as CEO in December 2024 to co-found AdvocateMH, a behavioral health triage startup. Board member Brian Reinken stepped in as interim CEO and president. Mou continued as chief medical officer in an advisory capacity. The transition marked the third CEO change in Cerebral's short history, underscoring persistent governance instability.
FTC distributes $5.1M in refunds to 40,249 consumers
The FTC announced that independent administrator Epiq Systems was distributing $5.1 million in refunds to 40,249 consumers who were charged after requesting subscription cancellation. Payments covered consumers who submitted cancellation requests on or before May 2022 but were billed anyway. Most received checks; those without addresses on file received PayPal payments.
Cerebral makes first acquisition, buying Resilience Lab
Cerebral acquired Resilience Lab, a behavioral health organization focused on clinician training and outcomes-focused care delivery. The acquisition brought Resilience Lab's proprietary clinical development platform, designed to reduce therapist turnover and burnout. The combined organization serves more than 100 million commercial insurance members under the Cerebral brand.
California class action pixel data breach settles for $500,000
Cerebral agreed to a $500,000 class action settlement to resolve the Doe v. Cerebral lawsuit over Meta pixel data sharing. The settlement covered California residents who received data breach notification letters in March 2023. Class members received pro rata cash payments and a $300 credit toward Cerebral services.
Cerebral raises $25M in new capital following Resilience Lab acquisition
Cerebral raised $25 million in capital approximately one month after its Resilience Lab acquisition, bringing total funding to roughly $487 million. The raise signaled continued investor confidence in the recovery strategy and funded the integration of Resilience Lab's clinician training infrastructure into Cerebral's platform.
Cerebral Institute opens proprietary training to external partner
Cerebral opened its Cerebral Institute clinician training program to its first external partner, Williamsburg Therapy Group. The Institute, built on Resilience Lab's methodology, achieved an 80% licensure rate for provisionally licensed therapists and 92% client engagement among Institute-certified clinicians. The external partnership signaled a pivot toward quality-focused revenue generation.
Evidence (42 citations)
D1: User Value Erosion
D2: Business Customer Exploitation
D3: Shareholder Extraction
D4: Lock-in & Switching Costs
D5: Twiddling & Algorithmic Opacity
D6: Dark Patterns
D7: Advertising & Monetization Pressure
D8: Competitive Conduct
D9: Labor & Governance
D10: Regulatory & Legal Posture
Scoring Log (4 entries)
Added 1 missing dimension narrative